Cheng Shujie, Sliva Daniel
Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, Indianapolis, IN, USA.
Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, Indianapolis, IN, USA Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
Integr Cancer Ther. 2015 May;14(3):249-57. doi: 10.1177/1534735414568721. Epub 2015 Jan 27.
The medicinal fungus Ganoderma lucidum has been used in traditional Chinese medicine for millennia to improve health and promote longevity. The idea of using G. lucidum for cancer treatment is based on numerous laboratory and preclinical studies with cancer and immune cells as well as animal models demonstrating various biological activities in vitro and in vivo. For example, G. lucidum possesses cytotoxic, cytostatic, antimetastatic, anti-inflammatory, and immunomodulating activities. Limited clinical studies, including case reports and randomized controlled trials, suggest G. lucidum as an alternative adjunct therapy for stimulating the immune system in cancer patients. To confirm the efficacy of G. lucidum in cancer treatment, systematic translational research programs should be started worldwide. In addition, only standardized preclinically evaluated, biologically active G. lucidum extracts should be used in alternative treatments. This approach will lead to the development of standardized G. lucidum preparations with specific chemical fingerprint-associated anticancer activities.
药用真菌灵芝在传统中医中已被使用了数千年,用于改善健康和延年益寿。将灵芝用于癌症治疗的想法基于众多针对癌症和免疫细胞以及动物模型的实验室和临床前研究,这些研究证明了其在体外和体内的各种生物活性。例如,灵芝具有细胞毒性、细胞抑制、抗转移、抗炎和免疫调节活性。包括病例报告和随机对照试验在内的有限临床研究表明,灵芝可作为一种替代辅助疗法,用于刺激癌症患者的免疫系统。为了证实灵芝在癌症治疗中的疗效,应在全球范围内启动系统的转化研究项目。此外,在替代治疗中应仅使用经过临床前标准化评估的具有生物活性的灵芝提取物。这种方法将导致开发出具有特定化学指纹相关抗癌活性的标准化灵芝制剂。